Thursday, September 23, 2021   23:41 EET



Development of anticancer nanoparticulate systems based on novel metal complexes

Project Code: PN-III-P2-2.1-PED2019-5143

Contract: 383PED / 2020


Financier: UEFISCDI

Coordinating Institution (CO) - „Stefan S. Nicolau” Institute of Virology

Partner (P1) - „Carol Davila” University of Medicine and Pharmacy

The research team from the „Stefan S. Nicolau” Institute of Virology (CO) comprises 7 senior researchers, 1 postdoctoral researcher and 2 PhD students.

The research team from the Faculty of Pharmacy from „Carol Davila” University of Medicine and Pharmacy (P1) comprises 7 senior researchers and 1 postdoctoral researcher.

Project duration: 24 months (23.10.2020 - 22.10.2022)

Project Manager: Dr. Mihaila Mirela Antonela, CSIII

e-mail: mihmirela@yahoo.com



A new generation of efficient metal-based drugs needs to be developed in order to overcome the biological, biopharmaceutical and biomedical drawbacks of standard chemotherapy. Use of metallo-drugs in cancer treatment has been hampered by an indaquate pharmacokinetic profile that limited the access to the biological target. This has led to the development of novel technologies based on nanostructured materials, acting as vectors for metallodrug delivery or simply as protectors of active species of the complexes for amplifying their activities and reducing their degradation. The aim of the project is to develop and validate new liposomal systems for transport and delivery of 2 promising anticancer agents previously studied by our research group. Nanoparticulate drug carrier systems will improve the therapeutic effectiveness and safety profile of these novel anticancer agents. The efficiency of these nanoformulations will be evaluated in terms of stability, drug entrapment efficiency, release behaviour, cell uptake, cytotoxicity, farmacotoxicology and pharmacokinetics. The project specific objectives are: 1) Development of liposomal systems validated at the laboratory level with novel anticancer agents; 2) Estimation the in vitro biological activity of the liposomal systems on various cell lines, including drug resistant cell lines, identifying biomarkers involved in modulating their biological activity; 3) Estimating the pharmaco-toxicological and pharmacokinetic profile of liposomal systems. Nanoparticles provide an enhanced bioavailability, in vivo stability, intestinal permeability, solubility, sustained and targeted delivery, therapeutic effectiveness of the anticancer drugs. The proposed project is a complex, interdisciplinary study related to biomedical international research, that aims to intends to transform modern methods, worldwide used in pharmacological, immunological and molecular biology studies, in instruments used for the translation to oncology.